HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Protein Powder Firm Faces Criminal Charges From Economic Adulteration

Executive Summary

American Pure Whey says on its website, "we are temporarily discontinuing the sale of products. Please check back in 7 days and you will be able to order our products." But firm previously warned by FDA about GMP deficiencies might want to recalculate how long sales will be stopped due to 41-count indictment on criminal charges.

You may also be interested in...



SIDI Supplier Protocol Update Adds To Burgeoning Self-Regulation Library

SIDI's draft protocol update incorporates changes to guide compliance with rules established by FSMA relevant to supplement firms and adds information on economically motivated adulteration and determining whether dietary ingredients are grandfathered as compliant under DSHEA.

At Supplement Regulation Table, Industry And FDA Target Dealing Out 'Quick Buck' Players

FDA's ODSP, says Director Steven Tave, found "how much there is in common between what our goals are at FDA and what your goals are in the industry." Trade group executives suggest changes both for the industry and FDA, though none expect noncompliant firms to fall into line short of being forced off the market.

Industry Roundup: NBTY Survey, GMP Warning, Ganeden Distribution

Supplement industry critic leads AG group; FTC cuts checks to Trudeau book buyers; NBTY appoints CFO; and more news in brief.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel